149 related articles for article (PubMed ID: 38399618)
21. Impact of the first-line antiretroviral therapy on soluble markers of inflammation in cohort of human immunodeficiency virus type 1 in Moroccan patients: a prospective study.
Haddaji A; Ouladlahsen A; Lkhider M; Bensghir R; Jebbar S; Hilmi S; Abbadi I; Sodqi M; Marih L; Pineau P; El Filali KM; Ezzikouri S
Arch Microbiol; 2023 May; 205(6):223. PubMed ID: 37154966
[TBL] [Abstract][Full Text] [Related]
22. High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.
Mboumba Bouassa RS; Mossoro-Kpinde CD; Gody JC; Veyer D; Péré H; Matta M; Robin L; Grésenguet G; Charpentier C; Bélec L
J Antimicrob Chemother; 2019 Jul; 74(7):2030-2038. PubMed ID: 30891603
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer.
Torres HA; Rallapalli V; Saxena A; Granwehr BP; Viola GM; Ariza-Heredia E; Adachi JA; Chemaly RF; Marfatia R; Jiang Y; Mahale P; Kyvernitakis A; Fanale MA; Mulanovich V
Clin Microbiol Infect; 2014 Oct; 20(10):O672-9. PubMed ID: 24529214
[TBL] [Abstract][Full Text] [Related]
24. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression.
Kleinmann WN; Pruszynski JE; Adhikari EH
Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101151. PubMed ID: 37689245
[TBL] [Abstract][Full Text] [Related]
25. Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression.
Hoenigl M; Moser CB; Funderburg N; Bosch R; Kantor A; Zhang Y; Eugen-Olsen J; Finkelman M; Reiser J; Landay A; Moisi D; Lederman MM; Gianella S;
Clin Infect Dis; 2019 Aug; 69(4):676-686. PubMed ID: 30418519
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study.
Santos JR; Casadellà M; Noguera-Julian M; Micán-Rivera R; Domingo P; Antela A; Portilla J; Sanz J; Montero-Alonso M; Navarro J; Masiá M; Valcarce-Pardeiro N; Ocampo A; Pérez-Martínez L; García-Vallecillos C; Vivancos MJ; Imaz A; Iribarren JA; Hernández-Quero J; Villar-García J; Barrufet P; Paredes R;
Front Cell Infect Microbiol; 2023; 13():1187999. PubMed ID: 37434782
[TBL] [Abstract][Full Text] [Related]
27. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
[TBL] [Abstract][Full Text] [Related]
28. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
[TBL] [Abstract][Full Text] [Related]
29. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.
Neesgaard B; Greenberg L; Miró JM; Grabmeier-Pfistershammer K; Wandeler G; Smith C; De Wit S; Wit F; Pelchen-Matthews A; Mussini C; Castagna A; Pradier C; d'Arminio Monforte A; Vehreschild JJ; Sönnerborg A; Anne AV; Carr A; Bansi-Matharu L; Lundgren JD; Garges H; Rogatto F; Zangerle R; Günthard HF; Rasmussen LD; Necsoi C; van der Valk M; Menozzi M; Muccini C; Peters L; Mocroft A; Ryom L
Lancet HIV; 2022 Jul; 9(7):e474-e485. PubMed ID: 35688166
[TBL] [Abstract][Full Text] [Related]
30. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
Byonanebye DM; Polizzotto MN; Neesgaard B; Sarcletti M; Matulionyte R; Braun DL; Castagna A; de Wit S; Wit F; Fontas E; Vehreschild JJ; Vesterbacka J; Greenberg L; Hatleberg C; Garges H; Gallant J; Volny Anne A; Öllinger A; Mozer-Lisewska I; Surial B; Spagnuolo V; Necsoi C; van der Valk M; Mocroft A; Law M; Ryom L; Petoumenos K;
HIV Med; 2022 Sep; 23(8):895-910. PubMed ID: 35233903
[TBL] [Abstract][Full Text] [Related]
31. Endothelial Glycocalyx Integrity in Treatment-Naïve People Living with HIV before and One Year after Antiretroviral Treatment Initiation.
Fragkou PC; Ikonomidis I; Benas D; Kavatha D; Moschopoulos CD; Protopapas K; Kostelli G; Thymis J; Mpirmpa D; Galani I; Tsakona M; Oikonomopoulou C; Theocharous G; Gorgoulis VG; Gallos P; Tsiodras S; Antoniadou A; Papadopoulos A; Triantafyllidi H
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515191
[TBL] [Abstract][Full Text] [Related]
32. Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.
Clemente T; Galli L; Lolatto R; Gagliardini R; Lagi F; Ferrara M; Cattelan AM; Focà E; Di Biagio A; Cervo A; Calza L; Maggiolo F; Marchetti G; Cenderello G; Rusconi S; Zazzi M; Santoro MM; Spagnuolo V; Castagna A;
BMJ Open; 2024 Feb; 14(2):e080606. PubMed ID: 38341206
[TBL] [Abstract][Full Text] [Related]
33. Metabolic Changes Associated With the Use of Integrase Strand Transfer Inhibitors Among Virally Controlled Women.
Summers NA; Lahiri CD; Angert CD; Aldredge A; Mehta CC; Ofotokun I; Kerchberger AM; Gustafson D; Weiser SD; Kassaye S; Konkle-Parker D; Sharma A; Adimora AA; Bolivar H; Cocohoba J; French AL; Golub ET; Sheth AN
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):355-362. PubMed ID: 33060420
[TBL] [Abstract][Full Text] [Related]
34. Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.
Nance RM; Vannappagari V; Smith K; Johannes CB; Calingaert B; Saltus CW; Mayer KH; Whitney BM; Rodriguez B; Moore RD; Eron JJ; Geng E; Mathews WC; Mugavero MJ; Saag MS; Kitahata MM; Delaney JAC; Crane HM
J Acquir Immune Defic Syndr; 2019 Aug; 81(5):572-577. PubMed ID: 31107299
[TBL] [Abstract][Full Text] [Related]
35. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
[TBL] [Abstract][Full Text] [Related]
36. Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Zhao X; Prajapati G; Tse J; Near AM; Kumar PN
Curr Med Res Opin; 2023 Jul; 39(7):997-1006. PubMed ID: 37334707
[TBL] [Abstract][Full Text] [Related]
37. Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide.
Hsu JY; Sun HY; Chen LY; Chang SY; Chuang YC; Huang YS; Su YC; Liu WC; Hung CC
J Glob Antimicrob Resist; 2024 Mar; 36():426-435. PubMed ID: 37923129
[TBL] [Abstract][Full Text] [Related]
38. Correlation between different methods to measure microbial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals.
Abad-Fernández M; Vallejo A; Hernández-Novoa B; Díaz L; Gutiérrez C; Madrid N; Muñoz MA; Moreno S
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):149-53. PubMed ID: 24047967
[TBL] [Abstract][Full Text] [Related]
39. Similar plasma lipidomic profile in people living with HIV treated with a darunavir-based or an integrase inhibitor-based antiretroviral therapy.
Mena A; Clavero E; Díaz-Díaz JL; Castro A
Sci Rep; 2019 Nov; 9(1):17184. PubMed ID: 31748628
[TBL] [Abstract][Full Text] [Related]
40. Polypharmacy and potential drug-drug interactions among people living with HIV in the era of integrase strand transfer inhibitor-based antiretroviral therapy.
Peng AT; Huang SH; Lee HY; Wu PY; Kuo HY; Hung CC
Int J Antimicrob Agents; 2024 Feb; 63(2):107067. PubMed ID: 38141835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
